Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
Ontology highlight
ABSTRACT: Many patients have cancers that have increased activity of a protein called STAT3 that contributes critically to the development and growth of their cancer. Despite our knowledge of STAT3’s importance to cancer, scientists and doctors have not developed a drug that targets it and that patients can take to treat their cancer more effectively than treatments that are now available. Tvardi Therapeutics, Incorporated has developed a compound, TTI-101, which can be given by mouth and acts as a direct inhibitor of STAT3. Administration of TTI-101 to mice demonstrated that it blocked growth of cancers of the breast, head and neck, lung, and liver and it was safe when administered at high doses to mice, rats, and dogs. In this application, Tvardi is proposing to further develop TTI-101 for treatment of solid tumors for which the prognosis is dismal. The investigators will determine how safe it is when administered to patients with cancer, determine whether an adequate dose can be administered to patients with cancer that will block STAT3 in their cancer, and determine whether treatment with TTI-101 leads to reduced growth of their cancer.
DISEASE(S): Squamous Cell Carcinoma Of Head And Neck,Gastric Adenocarcinoma,Melanoma,Colorectal Cancer,Non Small Cell Lung Cancer,Advanced Cancer,Hepatocellular Cancer,Carcinoma, Hepatocellular,Liver Neoplasms,Head And Neck Squamous Cell Carcinoma,Breast Cancer,Neoplasms
PROVIDER: 2247646 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA